Liquidia/$LQDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Liquidia
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Ticker
$LQDA
Sector
Primary listing
Employees
216
Headquarters
Website
Liquidia Metrics
BasicAdvanced
$6.4bn
293.39
$0.24
0.42
-
Price and volume
Market cap
$6.4bn
Beta
0.42
52-week high
$72.49
52-week low
$11.85
Average daily volume
1.9m
Financial strength
Current ratio
2.224
Quick ratio
1.983
Long term debt to equity
123.223
Total debt to equity
170.221
Interest coverage (TTM)
1.75%
Profitability
EBITDA (TTM)
46.627
Gross margin (TTM)
91.82%
Net profit margin (TTM)
7.74%
Operating margin (TTM)
15.81%
Effective tax rate (TTM)
14.95%
Revenue per employee (TTM)
$1,330,000
Management effectiveness
Return on assets (TTM)
9.05%
Return on equity (TTM)
28.18%
Valuation
Price to earnings (TTM)
293.395
Price to revenue (TTM)
21.574
Price to book
58.25
Price to tangible book (TTM)
62.14
Price to free cash flow (TTM)
158.754
Free cash flow yield (TTM)
0.63%
Free cash flow per share (TTM)
0.451
Growth
Revenue change (TTM)
1,936.66%
Earnings per share change (TTM)
-114.51%
3-year revenue growth (CAGR)
157.17%
3-year earnings per share growth (CAGR)
-24.85%
What the Analysts think about Liquidia
Analyst ratings (Buy, Hold, Sell) for Liquidia stock.
Liquidia Financial Performance
Revenues and expenses
Liquidia Earnings Performance
Company profitability
Liquidia News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs